Overview of Immunotherapy
Laura J. Zitella, R. Donald Harvey and Mollie Reed
Posted: 12/1/2017
Expires: 11/30/2018
Credits/Contact Hours: 2.25
Instructions for Earning CE credit
If you would like to earn credit, you must take the pre-test first by clicking here
Review CE information and Begin Pre-test
rowCount++;
var rowCount = 0;
rowCount++;
Quick Tips
Is programmed cell death ligand 1 (PD-L1) testing necessary?
When should you image patients to assess response to immunotherapy?
Why is pseudo-progression an important issue in patients on immune checkpoint inhibitors?
What are the mechanisms of action and adverse effects of these agents?
How do responses to immune checkpoint inhibitors differ from responses to chemotherapy?
What cancers are most likely to respond to immunotherapy?
How do you educate patients about the timing of early and latent side effects?
